Clinical utility of serum biomarkers for hepatocellular carcinoma

Biomarkers in MedicineVol. 15, No. 3 CommentaryClinical utility of serum biomarkers for hepatocellular carcinomaXin-Fei Xu‡, Lei Liang‡, Hao Xing‡, Feng Shen, Dong-Sheng Huang, Wan Yee Lau & Tian YangXin-Fei Xu‡ https://orcid.org/0000-0002-2398-4562Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China‡Authors contributed equallySearch for more papers by this author, Lei Liang‡Department of Hepatobiliary, Pancreatic & Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Zhejiang, China‡Authors contributed equallySearch for more papers by this author, Hao Xing‡Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China‡Authors contributed equallySearch for more papers by this author, Feng ShenDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, ChinaSearch for more papers by this author, Dong-Sheng HuangDepartment of Hepatobiliary, Pancreatic & Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Zhejiang, ChinaSearch for more papers by this author, Wan Yee LauDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, ChinaFaculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, ChinaSearch for more papers by this author & Tian Yang*Author for correspondence: E-mail Address: yangtiandfgd@hotmail.comDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, ChinaSearch for more papers by this authorPublished Online:20 Jan 2021https://doi.org/10.2217/bmm-2020-0474AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: AFPbiomarkerdiagnosisdisease modelinghepatocellular carcinomaindividual outcomesAFP-L3predictionPIVKA-IIReferences1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 391(10127), 1301–1314 (2018).Crossref, Medline, Google Scholar2. Tanaka M, Katayama F, Kato H et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J. Epidemiol. 21(6), 401–416 (2011).Crossref, Medline, Google Scholar3. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J. Hepatol. 72(2), 250–261 (2020).Crossref, Medline, CAS, Google Scholar4. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).Crossref, Medline, Google Scholar5. Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68(2), 723–750 (2018).Crossref, Medline, Google Scholar6. Johnson PJ, Pirrie SJ, Cox TF et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol. Biomarkers Prev. 23(1), 144–153 (2014).Crossref, Medline, CAS, Google Scholar7. Yang T, Xing H, Wang G et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin. Chem. 65(12), 1543–1553 (2019).Crossref, Medline, CAS, Google Scholar8. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 15(11), 1301–1314 (2009).Crossref, Medline, Google Scholar9. Trevisani F, D'Intino PE, Morselli-Labate AM et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 34(4), 570–575 (2001).Crossref, Medline, CAS, Google Scholar10. Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 20(2), 282–296 (2019).Crossref, Medline, CAS, Google Scholar11. Personeni N, Bozzarelli S, Pressiani T et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 57(1), 101–107 (2012).Crossref, Medline, CAS, Google Scholar12. Xu XF, Xing H, Han J et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 154(3), 209–217 (2019).Crossref, Medline, Google Scholar13. Zhu R, Yang J, Xu L et al. Diagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma: a meta-analysis. Gastroenterol. Res. Pract. 2014, 529314 (2014).Crossref, Medline, Google Scholar14. Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am. J. Gastroenterol. 91(7), 1380–1383 (1996).Medline, CAS, Google Scholar15. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 18(4), 990–997 (1993).Crossref, Medline, CAS, Google Scholar16. Okuda H, Nakanishi T, Takatsu K et al. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 85(4), 812–818 (1999).Crossref, Medline, CAS, Google Scholar17. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 21(37), 10573–10583 (2015).Crossref, Medline, CAS, Google Scholar18. Saeki I, Yamasaki T, Tanabe N et al. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS ONE 10(5), e0126649 (2015).Crossref, Medline, Google Scholar19. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin. Chim. Acta 313(1-2), 15–19 (2001).Crossref, Medline, CAS, Google Scholar20. Sterling RK, Jeffers L, Gordon F et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am. J. Gastroenterol. 102(10), 2196–2205 (2007).Crossref, Medline, Google Scholar21. Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1), 110–118 (2009).Crossref, Medline, CAS, Google Scholar22. Tada T, Kumada T, Toyoda H et al. Relationship between lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int. 25(4), 848–853 (2005).Crossref, Medline, CAS, Google Scholar23. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111(4), 996–1001 (1996).Crossref, Medline, CAS, Google Scholar24. Berhane S, Toyoda H, Tada T et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin. Gastroenterol. Hepatol. 14(6), 875–886.e6 (2016).Crossref, Medline, CAS, Google Scholar25. Yang JD, Addissie BD, Mara KC et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol. Biomarkers Prev. 28(3), 531–538 (2019).Crossref, Medline, Google Scholar26. Toyoda H, Kumada T, Osaki Y et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 4(12), 1528–1536 (2006).Crossref, Medline, CAS, Google Scholar27. Fox R, Berhane S, Teng M et al. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br. J. Cancer 110(8), 2090–2098 (2014).Crossref, Medline, CAS, Google Scholar28. Golubnitschaja O, Polivka J Jr, Yeghiazaryan K, Berliner L. Liquid biopsy and multiparametric analysis in management of liver malignancies: new concepts of the patient stratification and prognostic approach. EPMA J. 9(3), 271–285 (2018).Crossref, Medline, Google Scholar29. Lu M, Zhan X. The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J. 9(1), 77–102 (2018).Crossref, Medline, Google Scholar30. Goldstein E, Yeghiazaryan K, Ahmad A, Giordano FA, Fröhlich H, Golubnitschaja O. Optimal multiparametric set-up modelled for best survival outcomes in palliative treatment of liver malignancies: unsupervised machine learning and 3 PM recommendations. EPMA J. 11(3), 505–515 (2020).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByDiagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis29 August 2022 | Journal of Clinical Medicine, Vol. 11, No. 17Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort studyInternational Journal of Surgery, Vol. 105 Vol. 15, No. 3 Follow us on social media for the latest updates Metrics Downloaded 178 times History Received 9 August 2020 Accepted 25 September 2020 Published online 20 January 2021 Published in print February 2021 Information© 2021 Future Medicine LtdKeywordsAFPbiomarkerdiagnosisdisease modelinghepatocellular carcinomaindividual outcomesAFP-L3predictionPIVKA-IIAcknowledgmentsThe authors thank D Su (Abbott China) for the support of providing related medical literature and writing suggestion.Financial & competing interests disclosureFunding for the study was provided by the National Natural Science Foundation of China (no. 81672699 and 81972726, Yang). The funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript and decision to submit the manuscript for publication. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download